WO2024157205 - 1-AMINO-4-PHENYLPHTHALAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
National phase entry is expected:
Publication Number
WO/2024/157205
Publication Date
02.08.2024
International Application No.
PCT/IB2024/050721
International Filing Date
25.01.2024
Title **
[English]
1-AMINO-4-PHENYLPHTHALAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
[French]
DÉRIVÉS DE 1-AMINO-4-PHÉNYLPHTALAZINE UTILES POUR LE TRAITEMENT DE MALADIES NEURODÉGÉNÉRATIVES
Applicants **
TAKEDA PHARMACEUTICAL COMPANY LIMITED
Inventors
ADAMS, Mark E.
BROWN, Jason W.
CHANG, Edcon
SCHLEICHER, Kristin
TANG, Mingnam
ZHOU, Feng
SUN, Huikai
WANG, Zhen
Priority Data
63/441,438
26.01.2023
US
63/589,626
11.10.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4870 | |
| EPO | Filing, Examination, Granting | 31092 | |
| Japan | Filing, Examination, Granting | 3114 | |
| South Korea | Filing, Examination, Granting | 3915 | |
| USA | Filing, Examination, Granting | 22940 |
Total:
65,931
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula (1), to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders, and conditions associated with NLRP3.[French]
étant définis dans la description. La présente invention concerne également des matériaux et des procédés de préparation de composés de formule 1, des compositions pharmaceutiques qui les contiennent, et leur utilisation pour traiter des maladies, des troubles et des états associés à NLRP3.